Condition: Non-Hodgkin Lymphoma Refractory/ Relapsed · DLBCL - Diffuse Large B Cell Lymphoma · Mantle Cell Lymphoma (MCL) · Sponsor: LTZ Therapeutics, Inc.
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma
This description comes directly from the study's public registry record.
Sherry Unabia · 669-207-0084 · sherry.unabia@ltztherapeutics.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Roswell Park Cancer Institute | Buffalo, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - Bergen | New York, New York, United States | Recruiting |
| Tennessee Oncology | Nashville, Tennessee, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07121946